Advertisement
Advertisement
August 6, 2015
Penumbra to Distribute InspireMD's CGuard EPS in Europe and International Markets
August 7, 2015—InspireMD, Inc. announced that it has entered into a partnership with Penumbra, Inc. to distribute InspireMD’s carotid CGuard embolic protection system (EPS) through Penumbra’s direct commercialization team.
The CGuard EPS, which features the company's MicroNet technology, has received European CE Mark approval. The US Food and Drug Administration has not yet approved the CGuard EPS for sale in the United States, advised the company.
According to InspireMD, clinical trials of the CGuard EPS system, including the recent CARENET and PARADIGM studies, have continued to support the benefits of the MicroNet-enhanced CGuard system, resulting in increased commercial adoption in the European market.
Penumbra, which offers its own portfolios of neurovascular products and peripheral vascular products, has direct sales operations in North America, Europe, and Australia. The company sells through distributors in Asia and select other international markets.
Advertisement
Advertisement
